Pharmacoeconomic review report. Ocrelizumab (Ocrevus) (Hoffmann-La roche limited).
Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes B cells that express CD20, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult...
Saved in:
| Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534388/ Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Ottawa (ON) :
CADTH,
2017
|
| Series: | Common drug review clinical review report.
|
| Subjects: |
| Summary: | Ocrelizumab (Ocrevus) is a recombinant humanized monoclonal antibody that selectively targets and depletes B cells that express CD20, which are thought to contribute to the inflammatory and neurodegenerative pathogenesis of multiple sclerosis (MS). Ocrelizumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). It is available in 300 mg single-use vials for infusion. It is recommended that an initial 600 mg dose be administered as two separate intravenous (IV) infusions (initial 300 mg infusion followed by a second 300 mg infusion two weeks later), with subsequent ocrelizumab doses administered as single 600 mg IV infusions every six months. At the manufacturer's submitted unit price of $8,150 per 300 mg vial, ocrelizumab costs $32,600 per patient per year. The manufacturer's reimbursement request is per the Health Canada indication. |
|---|---|
| Item Description: | "Version 1.0." |
| Physical Description: | 1 online resource (1 PDF file (37 pages)) : illustrations. |
| Bibliography: | Includes bibliographical references. |
| Source of Description, Etc. Note: | Description based on online resource; title from PDF title page (viewed on February 1, 2019). |
| Funding Information Note: | Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec. |
